Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

EASD 2024

Keep up to date with the top stories from the 60th EASD Annual Meeting with our congress hub page.
ADVANCED SEARCH
Log in
Top
Diabetology International

02-09-2024 | Insulins | Mini-Review

Genetics of type-1 diabetes

Authors: Hiroshi Ikegami, Shinsuke Noso

Published in: Diabetology International

Login to get access

Abstract

Type-1 diabetes is a multifactorial disease characterized by genetic and environmental factors that contribute to its development and progression. Despite progress in the management of type-1 diabetes, the final goal of curing the disease is yet to be achieved. To establish effective methods for the prevention, intervention, and cure of the disease, the molecular mechanisms and pathways involved in its development and progression should be clarified. One effective approach is to identify genes responsible for disease susceptibility and apply information obtained from the function of genes in disease etiology for the protection, intervention, and cure of type-1 diabetes. In this review, we discuss the genetic basis of type-1 diabetes, along with prospects for its prevention, intervention, and cure for type-1 diabetes.
Literature
1.
Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus; Seino Y, Nanjo K, Tajima N,et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. Diabetol Int. 2010;1:2–20.
2.
Kawasaki E, Maruyama T, Imagawa A, et al. Diagnostic criteria for acute-onset type 1 diabetes mellitus (2012): Report of the Committee of Japan Diabetes Society on the Research of Fulminant and Acute-onset Type 1 Diabetes Mellitus. Diabetol Int. 2013;4:221–5.CrossRef
3.
Imagawa A, Hanafusa T, Awata T, et al. Report on the committee of the Japan Diabetes Society on the Research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus (2012). Diabetol Int. 2012;3:179–83.CrossRef
4.
Shimada A, Kawasaki E, Abiru N, et al. New diagnostic criteria (2023) for slowly progressive type 1 diabetes (SPIDDM): Report from Committee on Type 1 Diabetes of the Japan Diabetes Society (English version). Diabetol Int. 2024;15:1–4.PubMedCrossRef
5.
Patterson C, Guariguata L, Dahlquist G, et al. Diabetes in the young - a global view and worldwide estimates of numbers of children with type 1 diabetes. Diabetes Res Clin Pract. 2014;103:161–75.PubMedCrossRef
6.
Imagawa A, Hanafusa T. Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners. Nat Clin Prac Endocrinol Metab. 2007;3:36–45.CrossRef
7.
Ikegami H, Ogihara T. Genetics of insulin-dependent diabetes mellitus. Endocrine J. 1996;43:605–11.CrossRef
8.
Ikegami H, Kawabata Y, Noso S, et al. Genetics of type 1 diabetes in Asian and Caucasian populations. Diab Res Clin Prac. 2007;77(Suppl 1):S116–21.CrossRef
9.
10.
Hyttinen V, Kaprio J, Kinnunen L, et al. Genetic liability of type 1 diabetes and the onset age among 22,650 young Finnish twin pairs: a nationwide follow-up study. Diabetes. 2003;52:1052–5.PubMedCrossRef
11.
Ikegami H, Makino S. The NOD mouse and its related strains. In: Sima AAF, Shafrir E, editors. Animal Models of Diabetes A Primer. Amsterdam: Harwood Academic Publishers; 2000. p. 43–61.
12.
Komeda K, Noda M, Terao K, et al. Establishment of two substrains, diabetes-prone and non-diabetic, from Long-Evans Tokushima Lean (LETL) rats. Endocr J. 1998;45:737–44.PubMedCrossRef
13.
Ikegami H, Makino S, Harada M, et al. The cataract Shionogi mouse, a sister strain of the non-obese diabetic mouse: similar class II but different class I gene products. Diabetologia. 1988;31:254–8.PubMedCrossRef
14.
Ikegami H, Yano N, Sato T, et al. Immunogenetics and immunopathogenesis of the NOD mouse. In: Eisenbarth GS, editor., et al., Immunotherapy of diabetes and selected autoimmune diseases. Boca Raton: CRC Press; 1989. p. 22–33.
15.
Hattori M, Buse JB, Jackson RA, et al. The NOD mouse: recessive diabetogenic gene in the major histocompatibility complex. Science. 1986;231:733–5.PubMedCrossRef
16.
Wicker LS, Miller BJ, Coker LZ, et al. Genetic control of diabetes and insulitis in the nonobese diabetic (NOD) mouse. J Exp Med. 1987;165:1639–54.PubMedCrossRef
17.
Ikegami H, Makino S. Genetic susceptibility to insulin-dependent diabetes mellitus: from the NOD mouse to man. In: Shafrir E, editor. Frontiers in Diabetes Research: Lessons from Animal Diabetes IV. London: Smith-Gordon; 1993. p. 39–50.
18.
Ikegami H, Makino S, Ogihara T. Molecular genetics of insulin-dependent diabetes mellitus: analysis of congenic strains. In: Shafrir E, editor. Frontiers in Diabetes Research: Lessons from Animal Diabetes VI. Boston: Birkhauser; 1996. p. 33–46.CrossRef
19.
Kawabata Y, Ikegami H, Awata T, et al. Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset. Diabetologia. 2009;52:2513–21.PubMedCrossRef
20.
Awata T, Kawasaki E, Ikegami H, et al. Insulin gene/IDDM2 locus in Japanese type 1 diabetes: contribution of class I alleles and influence of class I subdivision in susceptibility to type 1 diabetes. J Clin Endocrinol Metab. 2007;92:1791–5.PubMedCrossRef
21.
Acha-Orbea H, McDevitt HO. The first external domain of the nonobese diabetic mouse class II I-A beta chain is unique. Proc Natl Acad Sci USA. 1987;84:2435–9.PubMedPubMedCentralCrossRef
22.
Ikegami H, Eisenbarth GS, Hattori M. Major histocompatibility complex-linked diabetogenic gene of the nonobese diabetic mouse: analysis of genomic DNA amplified by the polymerase chain reaction. J Clin Invest. 1990;85:18–24.PubMedPubMedCentralCrossRef
23.
Ikegami H, Makino S, Yamato E, et al. Identification of a new susceptibility locus for insulin-dependent diabetes mellitus by ancestral haplotype congenic mapping. J Clin Invest. 1995;96:1936–42.PubMedPubMedCentralCrossRef
24.
Inoue K, Ikegami H, Fujisawa T, et al. Allelic variation in class I K gene as candidate for second component of MHC-linked susceptibility to type 1 diabetes in NOD mouse. Diabetologia. 2004;47:739–47.PubMedCrossRef
25.
Hattori M, Yamato E, Itoh N, et al. Cutting edge: homologous recombination of the MHC class I K region defines new MHC-linked diabetogenic susceptibility gene(s) in nonobese diabetic mice. J Immunol. 1999;163:1721–4.PubMedCrossRef
26.
Awata T, Kuzuya T, Matsuda A, et al. Genetic analysis of HLA class II alleles and susceptibility to type 1 (insulin-dependent) diabetes mellitus in Japanese subjects. Diabetologia. 1992;35:419–24.PubMedCrossRef
27.
Ikegami H, Kawaguchi Y, Yamato E, et al. Analysis by the polymerase chain reaction of histocompatibility leucocyte antigen-DR9-linked susceptibility to insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1992;75:1381–5.PubMed
28.
Kawabata Y, Ikegami H, Kawaguchi Y, et al. Asian-specific HLA haplotypes reveal heterogeneity of the contribution of HLA-DR and -DQ haplotypes to susceptibility to type 1 diabetes. Diabetes. 2002;51:545–51.PubMedCrossRef
29.
Fujisawa T, Ikegami H, Yamato E, et al. Class I HLA is associated with age-at-onset of IDDM, while class II HLA confers susceptibility to IDDM. Diabetologia. 1995;38:1494.
30.
Kawabata Y, Ikegami H, Kawaguchi Y, et al. Age-related association of MHC class I chain-related gene A (MICA) with type I (insulin-dependent) diabetes mellitus. Hum Immunol. 2000;61:624.PubMedCrossRef
31.
Nejentsev S, Howson JM, Walker NM, et al. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature. 2007;450:887–92.PubMedPubMedCentralCrossRef
32.
Julier C, Hyer RN, Davies J, et al. Insulin-IGF2 region on chromosome 11p encodes a gene implicated in HLA-DR4-dependent diabetes susceptibility. Nature. 1991;354:155–9.PubMedCrossRef
33.
Lucassen AM, Julier C, Beressi JP, et al. Susceptibility to insulin dependent diabetes mellitus maps to a 4.1kb segment of DNA spanning the insulin gene and associated with VNTR. Nat Genet. 1993;4:305–10.PubMedCrossRef
34.
Kawaguchi Y, Ikegami H, Shen G-Q, et al. Insulin gene region contributes to genetic susceptibility to, but may not to low incidence of, insulin-dependent diabetes mellitus in Japanese. Biochem Biophys Res Commun. 1997;233:283–7.PubMedCrossRef
35.
Vafiadia P, Bennett ST, Todd JA, et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet. 1997;15:289–92.CrossRef
36.
Pugliese A, Zeller M, Fernandez A Jr, et al. The insulin gene is transcribed in the human thymus and transcription levels correlate with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet. 1997;15:293–6.PubMedCrossRef
37.
38.
Noso S, Kataoka K, Kawabata Y, et al. Insulin transactivator MafA regulates intra-thymic expression of insulin and affects susceptibility to type 1 diabetes. Diabetes. 2010;59:2579–87.PubMedPubMedCentralCrossRef
39.
Noso S, Kawabata Y, Babaya N, et al. Association study of MAFA and MAFB, genes related to organ-specific autoimmunity, with susceptibility to type 1 diabetes in Japanese and Caucasian populations. J Genet Syndr Gene Ther. 2013;4:204.CrossRef
40.
Bottini N, Musumeci L, Alonso A, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type 1 diabetes. Nat Genet. 2004;36:337–8.PubMedCrossRef
41.
Ueda H, Howson JMM, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature. 2003;423:506–11.PubMedCrossRef
42.
Lowe CE, Cooper JD, Brusko T, et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet. 2007;39:1074–82.PubMedCrossRef
43.
Ikegami H, Awata T, Kawasaki E, et al. The association of CTLA4 polymorphism with type 1 diabetes is concentrated in patients complicated with autoimmune thyroid disease: a multi-center collaborative study in Japan. J Clin Endocrinol Metab. 2006;91:1087–92.PubMedCrossRef
44.
Kawasaki E, Awata T, Ikegami H, et al. Systematic search for single nucleotide polymorphisms in a lymphoid tyrosine phosphatase (PTPN22) gene: Association between promoter polymorphism and type 1 diabetes in Asian populations. Am J Med Genet. 2006;140:586–93.PubMedCrossRef
45.
Awata T, Kawasaki E, Tanaka S, et al. Association of type 1 diabetes with two loci on 12q13 and 16p13 and the influence coexisting thyroid autoimmunity in Japanese. J Clin Endocrinol Metab. 2009;94:231–5.PubMedCrossRef
46.
Kawasaki E, Awata T, Ikegami H, et al. Genetic association between the IL2RA and mode of onset of type 1 diabetes in the Japanese population. J Clin Endocrinol Metab. 2009;94:947–52.PubMedCrossRef
47.
Yamashita H, Awata T, Kawasaki E, et al. Analysis of the HLA and non-HLA susceptibility loci in Japanese type 1 diabetes. Diabetes Metab Res Rev. 2011;27:844–8.PubMedCrossRef
48.
Ikegami H, Noso S, Babaya N, et al. Genetic basis of type 1 diabetes: similarities and differences between East and West. Rev Diabet Stud. 2008;5:64–72.PubMedPubMedCentralCrossRef
49.
50.
51.
Davies JL, Kawaguchi Y, Bennett ST, et al. A genome-wide search for human type 1 diabetes susceptibility genes. Nature. 1994;371:130–6.PubMedCrossRef
52.
Todd JA, Walker NM, Cooper JD, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet. 2007;39:857–64.PubMedPubMedCentralCrossRef
53.
Barrett JC, Clayton DG, Concannon P, et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet. 2009;41:703–7.PubMedPubMedCentralCrossRef
54.
55.
Robertson CC, Inshaw JRJ, Onengut-Gumuscu S, et al. Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes. Nat Genet. 2021;53:962–71.PubMedPubMedCentralCrossRef
56.
Todd JA, Mijovic C, Fletcher J, et al. Identification of susceptibility loci for insulin-dependent diabetes mellitus by trans-racial gene mapping. Nature. 1989;338:587–9.PubMedCrossRef
57.
Ikegami H, Noso S, Babaya N, et al. Genetics and pathogenesis of type 1 diabetes: prospects for prevention and intervention. J Diabetes Investig. 2011;2:415–20.PubMedPubMedCentralCrossRef
58.
Kawabata Y, Nishida N, Awata T, et al. A genome-wide association study confirming a strong effect of HLA and identifying variants in CSAD/lnc-ITGB7–1 on chromosome 12q13.13 associated with susceptibility to fulminant type 1 diabetes. Diabetes. 2019;68:665–75.PubMedCrossRef
59.
60.
Arany E, Strutt B, Romanus P, et al. Taurine supplement in early life altered islet morphology, decreased insulitis and delayed the onset of diabetes in non-obese diabetic mice. Diabetologia. 2004;47:1831–7.PubMedCrossRef
61.
Lin S, Yang J, Wu G, et al. Inhibitory effects of taurine on STZ-induced apoptosis of pancreatic islet cells. Adv Exp Med Biol. 2013;775:287–97.PubMedCrossRef
62.
Nakatsuru Y, Murase-Mishiba B-T M, et al. Taurine improves glucose tolerance in STZ-induced insulin-deficient diabetic mice. Diabetol Int. 2018;9:234–42.PubMedPubMedCentralCrossRef
63.
Noso S, Babaya N, Hiromine Y, et al. Metabolic signatures of β-cell destruction in type 1 diabetes. J Diabetes Investig. 2023;14:48–57.PubMedCrossRef
64.
65.
Olson ND, Wagner J, Dwarshuis N, et al. Variant calling and benchmarking in an era of complete human genome sequences. Nat Rev Genet. 2023;24:464–83.PubMedCrossRef
66.
Kishi A, Kawabata Y, Ugi S, et al. The onset of diabetes in three out of four sisters: a Japanese family with type 1 diabetes. a case report. Endocr J. 2009;56:767–72.PubMedCrossRef
67.
Ina Y, Kawabata Y, Sakamoto R, et al. A rare HLA genotype in two siblings with type 1 diabetes in a Japanese family clustered with type 1 diabetes. J Diabetes Investig. 2017;8:762–5.PubMedPubMedCentralCrossRef
68.
Ikegami H. Molecular genetics of type 1 diabetes. J Jpn Diabetes Soc. 2024;67:1–7.
69.
Noso S, Hosomichi K, Babaya N, et al. Whole-exome sequencing in rare families identified novel genetic variants for familial type 1 diabetes. Diabetologia. 2017;60(Suppl1):S24–5.
70.
Ikegami H, Babaya N, Noso S. Beta-cell failure in diabetes: common susceptibility and mechanisms shared between type 1 and type 2 diabetes. J Diabetes Investig. 2021;12:1526–39.PubMedPubMedCentralCrossRef
71.
Willyard C. Can autoimmune diseases be cured? Scientists see hope at last Nature. 2024;625:646–8.
72.
Dolgin E. How a pioneering diabetes drug offers hope for preventing autoimmune disorders. Nature. 2023;614:404–6.PubMedCrossRef
73.
Uno S, Imagawa A, Kozawa J, et al. Complete loss of insulin secretion capacity in type 1A diabetes patients during long-term follow up. J Diabetes Investig. 2018;9:806–12.PubMedCrossRef
74.
Keenan HA, Sun JK, Levine J, et al. Residual insulin production and pancreatic ß-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes. 2010;59:2846–53.PubMedPubMedCentralCrossRef
75.
Niwano F, Babaya N, Hiromine Y, et al. Glucose metabolism after pancreatectomy: opposite extremes between pancreaticoduodenectomy and distal pancreatectomy. J Clin Endocrinol Metab. 2021;106:e2203–14.PubMedPubMedCentralCrossRef
76.
Niwano F, Babaya N, Hiromine Y, et al. Three-year observation of glucose metabolism after pancreaticoduodenectomy: A single-center prospective study in Japan. J Clin Endocrinol Metab. 2022;107:3362–9.PubMedPubMedCentralCrossRef
77.
78.
Baumel-Alterzon S, Katz LS, Brill G, et al. Nrf2: the master and captain of beta cell fate. Trends Endocrinol Metab. 2021;32:7–19.PubMedCrossRef
79.
Meyerovich K, Ortis F, Allagnat F, et al. Endoplasmic reticulum stress and the unfolded protein response in pancreatic islet inflammation. J Mol Endocrinol. 2016;57:R1–17.PubMedCrossRef
80.
Hotta M, Tashiro F, Ikegami H, Niwa H, Ogihara T, Yodoi J, Miyazaki J-I. Pancreatic beta-cell-specific expression of thioredoxin, an antioxidative and anti-apoptotic protein, prevents autoimmune and streptozotocin-induced diabetes. J Exp Med. 1998;188:1445–51.PubMedPubMedCentralCrossRef
81.
Yamamoto M, Yamato E, Shu-Ichi T, Tashiro F, Ikegami H, Yodoi J, Miyazaki J. Transgenic Expression of Antioxidant Protein Thioredoxin in Pancreatic β Cells Prevents Progression of Type 2 Diabetes Mellitus. Antioxid Redox Sig. 2008;10:43–50.CrossRef
82.
Ikegami H, Fujisawa T, Ogihara T. Mouse models of type 1 and type 2 diabetes derived from the same closed colony: genetic susceptibility shared between two types of diabetes? ILAR J. 2004;45:267–76.CrossRef
83.
Dooley J, Tian L, Schonefeldt S, et al. Genetic predisposition for beta cell fragility underlies type 1 and type 2 diabetes. Nat Genet. 2016;48:519–27.PubMedPubMedCentralCrossRef
84.
Rutsch N, Chamberlain CE, Dixon W, et al. Diabetes with multiple autoimmune and inflammatory conditions linked to an activating SKAP2 mutation. Diabetes Care. 2021;44:1816–25.PubMedPubMedCentralCrossRef
85.
Hebbar P, Nizam R, John SE, et al. Linkage analysis using whole exome sequencing data implicates SLC17A1, SLC17A3, TATDN2 and TMEM131L in type 1 diabetes in Kuwaiti families. Sci Rep. 2023;13:14978.PubMedPubMedCentralCrossRef
Metadata
Title
Genetics of type-1 diabetes
Authors
Hiroshi Ikegami
Shinsuke Noso
Publication date
02-09-2024
Publisher
Springer Nature Singapore
Keywords
Insulins
Insulins
Published in
Diabetology International
Print ISSN: 2190-1678
Electronic ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-024-00754-1

2024 ESC Congress

Noise pollution dangerous for heart health

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Read more

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits